Rescue therapy outcomes with GP IIb/IIIa inhibitors: abciximab versus tirofiban/eptifibatide
| Outcome | Abciximab % (95% CI) | I2 | Tirofiban/Eptifibatide % (95% CI) | I2 | P Value |
|---|---|---|---|---|---|
| Postoperative clinical stroke | 14.0 (8.0–25.0) | 50 | 13.0 (4.0–33.0) | 77 | .86 |
| Postoperative infarct on imaging | 28.0 (19.0–39.0) | 44 | 37.0 (9.0–76.0) | 81 | .67 |
| Postoperative hemorrhage | 7.0 (4.0–10.0) | 0 | 14.0 (6.0–31.0) | 26 | .12 |
| Perioperative morbidity from stroke/hemorrhage | 12.0 (8.0–18.0) | 4 | 8.0 (4.0–16.0) | 3 | .30 |
| Perioperative mortality from stroke/hemorrhage | 6.0 (4.0–10.0) | 0 | 6.0 (3.0–12.0) | 0 | .16 |
| Long-term good neurologic outcome | 85.0 (79.0–89.0) | 0 | 78.0 (69.0–85.0) | 0 | .15 |
| Long-term morbidity | 14.0 (9.0–21.0) | 15 | 18.0 (11.0–29.0) | 19 | .37 |
| Recanalization rate | 66.0 (58.0–74.0) | 32 | 83.0 (68.0–91.0) | 60 | .05 |